Focused On-demand Library for Complement C4-B

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P0C0L5

UPID:

CO4B_HUMAN

Alternative names:

Basic complement C4; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 3

Alternative UPACC:

P0C0L5; A2BHY4; P01028; P78445; Q13160; Q13906; Q14033; Q14835; Q6U2E9; Q6U2G1; Q6U2I5; Q6U2L1; Q6U2L7; Q6U2L9; Q6U2M5; Q6VCV8; Q96SA7; Q9NPK5; Q9UIP5

Background:

Complement C4-B, also known as Basic complement C4, plays a pivotal role in the classical complement pathway. It binds covalently to immunoglobulins and immune complexes, enhancing the solubilization of immune aggregates. The protein exists in two isotypes, C4A and C4B, which differ in their binding capabilities, crucial for effective immune response.

Therapeutic significance:

Complement C4-B is intricately linked to systemic lupus erythematosus (SLE) and Complement component 4B deficiency. Variants affecting this protein increase susceptibility to SLE, highlighting its potential as a target for therapeutic intervention in autoimmune disorders.